KRAS is a critical proto-oncogene and molecular switch that is frequently mutated in human cancers.Oncogenic mutations,primarily at codons 12,13,and 61,lock KRAS into a GTPbound active state,thus resulting in constitu...KRAS is a critical proto-oncogene and molecular switch that is frequently mutated in human cancers.Oncogenic mutations,primarily at codons 12,13,and 61,lock KRAS into a GTPbound active state,thus resulting in constitutive signaling through downstream effectors such as RAF and phosphoinositide 3-kinase(PI3K)1.These alterations are highly prevalent in pancreatic cancer,colorectal cancer(CRC),and non-small cell lung cancer(NSCLC),and they drive tumor initiation,progression,and therapy resistance.展开更多
基金supported by the National Natural Science Foundation of China(Grant Nos.82472677,82404653,U25A20103,and 223B2704)the Natural Science Foundation of Shanghai(Grant No.23ZR1418900)the Natural Science Foundation of Chongqing(Grant No.CSTB2023NSCQ-MSX0367).
文摘KRAS is a critical proto-oncogene and molecular switch that is frequently mutated in human cancers.Oncogenic mutations,primarily at codons 12,13,and 61,lock KRAS into a GTPbound active state,thus resulting in constitutive signaling through downstream effectors such as RAF and phosphoinositide 3-kinase(PI3K)1.These alterations are highly prevalent in pancreatic cancer,colorectal cancer(CRC),and non-small cell lung cancer(NSCLC),and they drive tumor initiation,progression,and therapy resistance.
